{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:53:29Z","timestamp":1761893609434,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":632,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To compare the ratio of free prostate specific antigen (fPSA), total PSA (tPSA) and complexed PSA (cPSA, measured using a novel immunoassay) with other variables used to detect prostate cancer in patients with intermediate serum PSA levels of 4.1\u201310.0\u2003ng\/mL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods\u2002<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>From July 1997 to August 1998, 140 consecutive patients were assessed; all had intermediate serum PSA levels and\/or abnormal findings on a digital rectal examination. All patients underwent transrectal ultrasonography (TRUS)\u2010guided biopsy, and the prostate and transition zone volumes were determined by TRUS. Free and tPSA were measured using the Tandem\u2010R assay (Hybritech Corp., San Diego, CA). PSA complexed with \u03b11\u2010antichymotrypsin (cPSA) was measured using an appropriate assay. The ability of cPSA, free\u2010to\u2010total PSA ratio (f\/tPSA), free\u2010to\u2010complexed PSA ratio (f\/cPSA), tPSA density of the whole prostate (PSAD), of the transition zone (tPSATZ), and cPSA density of the whole prostate (cPSAD) and of the transition zone (cPSATZ) to improve the power of PSA in detecting prostate cancer was evaluated using receiver operating characteristic (ROC) curves.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Of the 140 patients, 126 had histologically confirmed benign disease and 14 had prostate cancer. The cPSA alone had better specificity for detecting prostate cancer than had tPSA alone but the difference was not significant. The area under the ROC curve for f\/cPSA was larger than those for all other variables. With a 93% sensitivity for detecting prostate cancer, a f\/cPSA threshold of 25% would result in fewer unnecessary biopsies (40% f\/cPSA specificity) than with all other PSA variables. The difference in the resolution was significant between f\/cPSA and tPSA, cPSA, tPSAD and tPSATZ, but not with f\/tPSA, cPSAD or cPSATZ. In patients with a prostate volume of &lt;\u200330\u2003mL, the cPSATZ showed better specificity for prostate cancer than tPSA alone.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Measuring the level of cPSA and its derivatives may provide better differentiation of prostate cancer and benign disease than tPSA alone in patients with a tPSA level of 4.1\u201310.0\u2003ng\/mL.<\/jats:p>","DOI":"10.1046\/j.1464-410x.2000.00602.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:52:27Z","timestamp":1047351147000},"page":"708-714","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The significance of the free\u2010to\u2010complexed prostate\u2010specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1\u201310.0\u2003ng\/mL"],"prefix":"10.1111","volume":"85","author":[{"given":"T.","family":"Okegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nutahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38491-4"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35233-3"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37394-9"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37393-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","article-title":"Serum prostate specific antigen in a community\u2010based population of healthy man: establishment of age\u2010specific reference ranges","volume":"270","author":"Oesterling JE","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(94)90170-8"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530150038031"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64961-9"},{"key":"e_1_2_5_10_2","first-page":"222","article-title":"A complex between prostate\u2010specific antigen and alpha 1\u2010antichymotrypsin is the major form of prostate\u2010specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer","volume":"51","author":"Stenman UH","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/37.9.1618"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1 <230::AID-CNCR2820701310>3.0.CO;2-Y"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/clinchem\/41.10.1480","article-title":"Free and complexed prostate\u2010specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA\u2010alpha 1\u2010antichymotrypsin complex","volume":"41","author":"Pettersson K","year":"1995","journal-title":"Clin Chem"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/clinchem\/44.6.1216","article-title":"Novel immunoassay for the measurement of complexed prostate\u2010specific antigen in serum","volume":"44","author":"Allard WJ","year":"1998","journal-title":"Clin Chem"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38508-7"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1996)10:3<155::AID-JCLA8>3.0.CO;2-A"},{"key":"e_1_2_5_17_2","first-page":"681","article-title":"Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha\u20101\u2010antichymotrypsin","volume":"20","author":"Lilja H.","year":"1993","journal-title":"Urol Clin N Amer"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.143.1.7063747"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.3.6878708"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00241-6"},{"key":"e_1_2_5_21_2","first-page":"208(A796)","article-title":"Complexed PSA. results of a multicenter biopsy experience","volume":"161","author":"Brawer MK","year":"1999","journal-title":"J Urol"},{"key":"e_1_2_5_22_2","first-page":"234(A895)","article-title":"Is complexed PSA alone clinically useful?","volume":"159","author":"Sokoll LJ","year":"1998","journal-title":"J Urol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65405-3"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62911-2"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1998.00696.x"},{"key":"e_1_2_5_26_2","first-page":"147(A575)","article-title":"Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA\u2010ACT","volume":"157","author":"Wang TJ","year":"1997","journal-title":"J Urol"},{"key":"e_1_2_5_27_2","first-page":"S255(A664)","article-title":"PSA\u2010ACT immunoassay. Problems and solutions","volume":"42","author":"Chan DW","year":"1996","journal-title":"Clin Chem"},{"key":"e_1_2_5_28_2","first-page":"S236(A604)","article-title":"Development of an immunoassay specific for the PSA\u2010ACT complex in serum without interference of non\u2010specific adsorption","volume":"43","author":"Zhang P","year":"1997","journal-title":"Clin Chem"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00486-4"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00080-1"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.2000.00602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410x.2000.00602.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:01:07Z","timestamp":1761735667000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410x.2000.00602.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1046\/j.1464-410x.2000.00602.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.2000.00602.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2000,4]]},"assertion":[{"value":"2001-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}